Condition: Agitation · Alzheimer's Type Dementia · Sponsor: Suven Life Sciences Limited
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
This description comes directly from the study's public registry record.
Study Contact · +9140 2319 3956 · agitation@suven.com
Always discuss trial participation with your own doctor first.
| Advanced Research Center, Inc. | Anaheim, California, United States | Recruiting |
| ATP Clinical Research, Inc. | Costa Mesa, California, United States | Recruiting |
| Leading Edge Research LA, LLC | Encino, California, United States | Recruiting |
| Neuro Pain Medical Center | Fresno, California, United States | Recruiting |
| Neurology Center of North Orange County | Fullerton, California, United States | Recruiting |
| Mary S Easton Center for Alzheimer's Research and Care UCLA | Los Angeles, California, United States | Recruiting |
| Ki Health Partners, LLC | Stamford, Connecticut, United States | Recruiting |
| Allied Biomedical Research Institute | Miami, Florida, United States | Recruiting |
| Central Miami Medical Institute | Miami, Florida, United States | Recruiting |
| CCM Clinical Research Group | Miami, Florida, United States | Recruiting |
| Miami Jewish Health | Miami, Florida, United States | Recruiting |
| Novel Clinical Research Center, LLC. | Miami, Florida, United States | Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05397639